Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01

HLA class I supertypes: a revised and updated classification

John Sidney, Bjoern Peters, Nicole Frahm et al. · BMC Immunology · 2008 · 806 citations · Full text

Life Sciences, Genetics, Immunology +17

HLA-A2.1–restricted Education and Cytolytic Activity of CD8+ T Lymphocytes from β2 Microglobulin (β2m) HLA-A2.1 Monochain Transgenic H-2Db β2m Double Knockout Mice

Steve Pascolo, Nathalie Bervas, Jan Ure et al. · The Journal of Experimental Medicine · 1997 · 483 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6′-dibehenate)—A novel adjuvant inducing both strong CMI and antibody responses

Jesper Rømhild Davidsen, Ida Rosenkrands, Dennis Christensen et al. · Biochimica et Biophysica Acta (BBA) - Biomembranes · 2005 · 341 citations

Pharmacy, Biochemistry, Immunology +17

Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs

Lin Shen, Susan Peterson, Ahmad R. Sedaghat et al. · Nature Medicine · 2008 · 332 citations · Full text

Medicine, Pharmacology, Dose-response Modeling +10

Cationic Liposomes Formulated with Synthetic Mycobacterial Cordfactor (CAF01): A Versatile Adjuvant for Vaccines with Different Immunological Requirements

Else Marie Agger, Ida Rosenkrands, Jon Hansen et al. · PLoS ONE · 2008 · 289 citations · Full text

Pharmacy, Immunology, Infectious Diseases +17